A recent study suggests that patients who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds at a significantly accelerated pace than those who end traditional lifestyle regimens.
Published data in a leading health publication demonstrates that while obese people often shed substantial amounts of their total mass while on the medication, the mass returns at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing these drugs need to be aware of the danger of rapid rebound weight gain when the therapy is stopped," stated lead investigator Dr. Susan Jebb.
This pace of regain implies a return to pre-treatment weight within about 18 months.
Weighing Treatments
The research, which looked at 37 of trials involving thousands of participants, compared the effects of GLP-1 agonists with other pills.
The team note that individuals who shed pounds through dieting typically see a slower weight regain—approximately 100 grams monthly—post-intervention.
Explaining the Rapid Rebound
Nutrition scientists suggest the mode of action of the drugs explains the heightened weight return.
GLP-1 drugs imitate a natural hormone called glucagon-like peptide-1, which controls hunger.
"Artificially providing the hormone levels far above than normal may cause the system to produce less of its endogenous GLP-1, and could lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication means hunger is unsuppressed, making excessive eating far more likely."
A Lifelong Condition?
Health authorities recommend the injections for people with weight-linked health risks, alongside recommended diet and exercise modifications.
Professionals argue that, given the high risk of relapse, the therapy is often long-term.
This opinion is supported by drug manufacturers, who note that the results "highlight the persistent character of obesity," comparing it to managing conditions like hypertension.
Patient Accounts
People who have come off the medication explain a powerful return of cravings.
"I experienced something flipping and I was suddenly starving," recalled an individual.
This difficulty is exacerbated if patients have not developed permanent lifestyle or habit changes during treatment.
Significant Adoption
Survey data show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Use is greater among females than men.
- The 40s and 50s age group shows the greatest usage rates.
- Many access the medications through private healthcare rather than the NHS.
Finally, clinicians emphasize that while GLP-1 drugs are powerful agents for shedding pounds, they are not a magic solution and lasting health benefits hinges on ongoing behavioural support.
